Cell conversion specialist Mogrify has announced a collaboration and licence agreement with US genomic medicine company Sangamo Therapeutics.
Under the deal, Brisbane-based Sangamo has an exclusive licence to develop allogeneic cell therapies from Mogrifys proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs).
Dr Darrin Disley, CEO of Cambridge Science Park-based Mogrify, said: Mogrify is delighted to announce its second commercial deal with a US biopharma and the first in the exciting field of T cell immunotherapy.
The combination of Mogrifys proprietary systematic cell conversion technology and Sangamos regulatory T cell platform and proprietary ZFP (zinc finger protein) platform is a natural fit. Sangamo is at the forefront of the development of a world-class engineered ZFP genome editing platform and we are very happy to be partnering with such an innovative company.
Mogrify will receive an upfront payment and is eligible for additional payments related to development and regulatory milestones, and product sales.
Jason Fontenot, SVP, head of cell therapy at Sangamo, said: This licence agreement provides Sangamo with access to Mogrifys cell conversion technology, which will diversify our options as we develop off-the-shelf allogeneic CAR-Treg (chimeric antigen receptor regulatory T cell) cell therapies.
We expect this collaboration to accelerate our development of scalable and accessible CAR-Treg cell therapies, so that we can potentially deliver treatments to patients with inflammatory and autoimmune diseases more rapidly.
Mogrifys technology enables the transformation of any human cell type into any other human cell type.
It uses transcription factors or small molecules identified using proprietary big data technologies.
iPSCs and ESCs provide an evergreen starting material for the generation of Tregs. They enable more complex engineering and greater manufacturing scalability.
This could make the resulting therapies more cost-effective and therefore accessible to more patients.
Mogrify will discover and optimise the cell conversion technology from iPSCs or ESCs to regulatory T cells under the agreement, while Sangamo will be granted exclusive rights to use Mogrifys technology to create Tregs from iPSCs or ESCs.
Sangamo expects to use its ZFP gene-engineering technology and therapeutic development capabilities to transform these Tregs into novel off-the-shelf allogeneic CAR-Treg cell therapy candidates.
It aims to take them from clinical development through to registration for the treatment of inflammatory and autoimmune diseases.
Mogrify won the One to Watch award at the 2019 Cambridge Independent Science and Technology Awards.
Read more
Inivata launches RaDaR test to identify residual disease and relapse in cancer patients
Reversing osteoarthritis: Mogrify secures $1.1m from SBRI Healthcare to assess cartilage regeneration therapy
Mogrify cell therapy technology attracts further $16m funding
Darrin Disley returns to lead Mogrifys new cell revolution
Watch the highlights and see the pictures from the Cambridge Independent Science and Technology Awards 2019
Continue reading here:
Mogrify strikes deal with US biopharma Sangamo Therapeutics - Cambridge Independent
- Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks - Nature.com - March 28th, 2024
- Synthetic Circuits Reveal the Key to Rewinding the Cellular Clock - The Scientist - March 13th, 2024
- synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy - Nature.com - March 3rd, 2024
- Breaking through new research barriers with iPSC technology - News-Medical.Net - February 15th, 2024
- Abu Dhabi Stem Cells Centre partners with Rege Nephro and Kyoto University's Center for iPS Cell Research and ... - Abu Dhabi Media Office - January 12th, 2024
- Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro - ZAWYA - January 12th, 2024
- Efficient and reproducible generation of human induced pluripotent stem cell-derived expandable liver organoids for ... - Nature.com - December 23rd, 2023
- Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming - Nature.com - December 15th, 2023
- Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform - PR Newswire - December 13th, 2023
- CRISPRi gene modulation and all-optical electrophysiology in post-differentiated human iPSC-cardiomyocytes ... - Nature.com - December 7th, 2023
- World Hindu Congress 2023: Know all about the sessions and speakers - Organiser - November 23rd, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS ... - Business Wire - November 21st, 2023
- Efficient protocol for the differentiation of kidney podocytes from ... - Nature.com - November 17th, 2023
- Vitamin B12 is a limiting factor for induced cellular plasticity and ... - Nature.com - November 17th, 2023
- Study reveals the critical role of microglia in human brain development - Medical Xpress - November 15th, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600 million Japanese yen (approximately $4 million USD) through... - November 15th, 2023
- Who are the leading innovators in iPSCs for the pharmaceutical ... - Pharmaceutical Technology - November 7th, 2023
- Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous... - November 5th, 2023
- Systematic differences in discovery of genetic effects on gene ... - Nature.com - October 21st, 2023
- Pairwise biosynthesis of ion channels stabilizes excitability and ... - pnas.org - October 11th, 2023
- Scientists find multitude of genes associated with autism - The Statesman - October 9th, 2023
- Stem Cell Banking Market is Expected to Reach USD 16,474.30 ... - Digital Journal - October 7th, 2023
- Probing the individuality of cells and molecules - Open Access Government - October 5th, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Manchestertimes - October 3rd, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Business Wire - September 29th, 2023
- Less Funding to More Researchers Gets Nobel-level Results, Study ... - The Japan News - September 27th, 2023
- Brentuximab Vedotin Plus AVD Gets Positive CHMP Opinion for ... - OncLive - September 20th, 2023
- DKMS BMST Foundation India and Kokilaben Hospital unite to spread awareness about the Importance of Stem Cell Donation on World Marrow Donor Day - APN... - September 18th, 2023
- Vitamin B6 is governed by the local compartmentalization of ... - Science - September 14th, 2023
- Dolly the sheep creator Ian Wilmut dies aged 79 - BBC - September 14th, 2023
- Scientist who created Dolly the sheep dies aged 79: Professor Sir Ian Wilmut passes away five years after reve - Daily Mail - September 11th, 2023
- The global kits market is expected to grow at a CAGR of 7.4% from ... - Digital Journal - September 8th, 2023
- Eterna Therapeutics Announces Initiation of Development Activities ... - PipelineReview.com - September 8th, 2023
- Tokyo: 100 Years of Urban Regeneration / Tokyo's Nihonbashi Area ... - The Japan News - August 31st, 2023
- Transcriptome-based prediction of drugs, inhibiting ... - Nature.com - August 30th, 2023
- From the birds and the bees to IVG - The Gauntlet - August 26th, 2023
- Breakthrough creates stem cells without any memories - Freethink - August 26th, 2023
- Aging impairs the neurovascular interface in the heart - Science - August 26th, 2023
- For This Venture Capitalist, Research on Aging Is Personal; 'Bob ... - The Wall Street Journal - August 22nd, 2023
- Unleashing Potential: Illuminating the Future of Healthcare through Revolutionary Induced Pluripotent Stem Cel - openPR - August 18th, 2023
- A 'memory wipe' for stem cells may be the key to better therapies - The Conversation - August 16th, 2023
- Erasing epigenetic 'memory' to improve the quality of stem cells - FierceBiotech - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Business Wire - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Valdosta Daily Times - August 11th, 2023
- Advancing Clinical Trials with iPSC-Derived Liver Organoids - Microbioz India - August 11th, 2023
- Activation of cAMP (EPAC2) signaling pathway promotes hepatocyte ... - Nature.com - August 1st, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of Aging Damage Reversal Showing GIVI-MPC Stem Cell Therapys Ability to Create New Skeletal... - July 30th, 2023
- Femtech in Japan: An Industry on the Rise - Femtech Insider - July 28th, 2023
- Association between enhanced carbonyl stress and decreased ... - Nature.com - July 28th, 2023
- Defects in early synaptic formation and neuronal function in Prader ... - Nature.com - July 27th, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of ... - Business Wire - July 25th, 2023
- Cure to Autism and Alzheimer's May Be in Space, Says 1st Brazilian Scientist who Will Be on The ISS - Folha de S.Paulo - July 25th, 2023
- Futurama's Resurrection Ruins The Perfect Ending (& Shows Must ... - Looper - July 25th, 2023
- University Of Massachusetts Amherst's Team Bags Honour Of 2023 Armstrong Fund For Science Award - India Education Diary - July 20th, 2023
- Scientists working on IVG, a new reproductive method that can make human babies in labs - IndiaTimes - July 19th, 2023
- Co-transplantation of autologous Treg cells in a cell therapy for ... - Nature.com - July 13th, 2023
- Magic Valley and Biocellion Join Forces to Improve Bioreactor Tech ... - vegconomist - the vegan business magazine - July 13th, 2023
- IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ... - Tullahoma News and Guardian - July 10th, 2023
- Hitachi : forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT - Marketscreener.com - July 6th, 2023
- Cell therapy limitations with iPS-based multi-cell therapeutics - Drug Target Review - July 6th, 2023
- Remembering Dolly- The Clone Sheep On Her Birth Anniversary - Free Press Journal - July 4th, 2023
- Labs and Translational Research - UMass Medical School - June 28th, 2023
- Cellusion raises 2.83B series C round to progress iPS cell-derived ... - BioWorld Online - June 14th, 2023
- Japan-based Fujifilm introduces first-of-its-kind human iPSC-derived ... - BSA bureau - June 6th, 2023
- ALS: Parkinson's drug ropinirole may be an effective treatment - Medical News Today - June 4th, 2023
- Scientists predict lab-grown babies in five years - Kidspot - June 4th, 2023
- Lab-grown babies could become a reality within five years - Earth.com - May 26th, 2023
- Leading healthcare experts from MENA and beyond to explore the future of precision medicine in the region at PMES 23 this month - ZAWYA - May 24th, 2023
- Long-Awaited Ax-2 Mission Launches, Heads to Space Station - AmericaSpace - May 22nd, 2023
- Eterna Therapeutics and Factor Bioscience Announce New Data on ... - GlobeNewswire - May 17th, 2023
- Research Assistant job with UNITED ARAB EMIRATES ... - Times Higher Education - May 10th, 2023
- Regulation of synaptic connectivity in schizophrenia spectrum by ... - Nature.com - April 29th, 2023
- Researchers Discover Key Role of Glucose in Brain Activity - Laboratory Equipment - April 25th, 2023
- Structure of Huntington's Protein Revealed - Technology Networks - April 21st, 2023
- Study of brain immune cell infection may explain long COVID ... - NHK WORLD - April 19th, 2023
- The Mechanism That Regulates Activity of Memory Gene - Neuroscience News - April 19th, 2023
- The IPO Buzz: CytoMed Therapeutics Prices its Micro-Cap IPO at ... - IPOScoop - April 19th, 2023
- Macomics Presents its ENIGMAC Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR - Yahoo Finance - April 19th, 2023
- Modulation of tau tubulin kinases (TTBK1 and TTBK2) impacts ... - Nature.com - April 19th, 2023
- A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves ... - pnas.org - April 16th, 2023
Recent Comments